LYELL IMMUNOPHARMA INC (LYEL)
US55083R1041 - Common Stock
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -203.99M | -234.63M | -183.12M | -250.22M | -204.47M | |||
| Depreciation Amortization | 19.66M | 20.25M | 18.02M | 13.62M | 4.29M | |||
| Change In Working Capital | -1.43M | 3.42M | -82.02M | 4.02M | -340.00K | |||
| Other non cash items | 29.97M | 47.27M | 77.56M | 106.33M | 39.64M | |||
| OPERATING CASH FLOW | -155.79M | -163.69M | -169.56M | -126.25M | -160.87M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -446.00K | -2.69M | -24.28M | -65.50M | -51.48M | |||
| Other Investing Activity | -31.33M | 186.73M | 12.74M | -56.07M | -222.04M | |||
| INVESTING CASH FLOW | -31.77M | 184.05M | -11.54M | -121.57M | -273.52M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Stock Issued/Repurchased | 1.84M | 2.20M | 11.10M | 401.24M | 476.79M | |||
| Other Financing Activity | -203.00K | -457.00K | -460.00K | N/A | N/A | |||
| FINANCING CASH FLOW | 1.65M | 1.74M | 10.64M | 401.24M | 476.79M | |||
| CHANGE IN CASH | -185.91M | 22.10M | -170.46M | 153.42M | 42.40M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -155.79M | -163.69M | -169.56M | -126.25M | -160.87M | |||
| Capital Expenditure | -446.00K | -2.69M | -24.28M | -65.50M | -51.48M | |||
| FREE CASH FLOW | -156.23M | -166.38M | -193.84M | -191.75M | -212.35M | |||
All data in USD